In March of this year, DeNovX and MIT finalized details of a collaborative agreement to continue development of patented continuous flow crystallization methods. This effort is sponsored by the National Institutes of Health through a Phase II SBIR award to DeNovX, and the work seeks to improve manufacturing-scale crystallization of pharmaceuticals by leveraging the unparalleled efficiency and safety advantages of continuous flow manufacturing.